TY - JOUR
T1 - Plasma cystatin C and high-density lipoprotein are important biomarkers of Alzheimer's disease and vascular dementia
T2 - A cross-sectional study
AU - Wang, Rui
AU - Chen, Zhaoyu
AU - Fu, Yongmei
AU - Wei, Xiaobo
AU - Liao, Jinchi
AU - Liu, Xu
AU - He, Bingjun
AU - Xu, Yunqi
AU - Zou, Jing
AU - Yang, Xiaoyan
AU - Weng, Ruihui
AU - Tan, Sheng
AU - McElroy, Christopher
AU - Jin, Kunlin
AU - Wang, Qing
N1 - Funding Information:
This work was supported by the National Natural Science Foundation of China (Grant No. 81271427, 81471291), Science and Technology Program of Guangdong of China (2016A050502019), Natural Science Foundations of Guangdong of China (2014A020212068), Guangdong Province Key Laboratory of Brain Function and Disease Foundation, Fundamental Research Funds for the Central Universities (16ykjc22), and Scientific Research Foundation of Guangzhou (2014J4100210) to QW.
Publisher Copyright:
© 2017 Wang, Chen, Fu, Wei, Liao, Liu, He, Xu, Zou, Yang, Weng, Tan, McElroy, Jin and Wang.
PY - 2017/2/7
Y1 - 2017/2/7
N2 - Objectives: Cystatin C (Cys C) and high-density lipoprotein (HDL) play critical roles in neurodegenerative diseases, such as dementia, Alzheimer's disease (AD) and vascular dementia (VaD). However, whether they can be used as reliable biomarkers to distinguish patients with dementia from healthy subjects and to determine disease severity remain largely unknown. Methods: We conducted a cross-sectional study to determine plasma Cys C and HDL levels of 88 patients with dementia (43 AD patients, 45 VaD patients) and 45 healthy age-matched controls. The severity of dementia was determined based on the Schwab and England Activities of Daily Living (ADL) Scale, the Mini-mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Lawton Instrumental ADL (IADL) Scale, and the Hachinski Ischemia Scale (Hachinski). Receiver operating characteristic (ROC) curves were calculated to determine the diagnostic accuracy of Cys C and HDL levels in distinguishing patients with dementia from healthy subjects. Results: We found that plasma Cys C levels were higher, but HDL levels were lower in AD and VaD patients respectively, compared to healthy control subjects. Yet, Cys C levels were highest among patients with VaD. Interestingly, plasma Cys C levels were significantly correlated with IADL Scale scores. In addition, the ROC curves for Cys C (area under the curve, AUC 0.816 for AD, AUC 0.841 for VaD) and HDL (AUC 0.800 for AD, AUC 0.731 for VaD) exhibited potential diagnostic value in distinguishing AD/VaD patients from healthy subjects. While the ROC curve for the combination of Cys C and HDL (AUC 0.873 for AD, AUC 0.897 for VaD) showed higher diagnostic accuracy in distinguishing AD/VaD patients from healthy subjects than the separate curves for each parameter. Conclusions: Our findings suggest that the inflammatory mediators Cys C and HDL may play important roles in the pathogenesis of dementia, and plasma Cys C and HDL levels may be useful screening tools for differentiating AD/VaD patients from healthy subjects.
AB - Objectives: Cystatin C (Cys C) and high-density lipoprotein (HDL) play critical roles in neurodegenerative diseases, such as dementia, Alzheimer's disease (AD) and vascular dementia (VaD). However, whether they can be used as reliable biomarkers to distinguish patients with dementia from healthy subjects and to determine disease severity remain largely unknown. Methods: We conducted a cross-sectional study to determine plasma Cys C and HDL levels of 88 patients with dementia (43 AD patients, 45 VaD patients) and 45 healthy age-matched controls. The severity of dementia was determined based on the Schwab and England Activities of Daily Living (ADL) Scale, the Mini-mental State Examination (MMSE), the Global Deterioration Scale (GDS), the Lawton Instrumental ADL (IADL) Scale, and the Hachinski Ischemia Scale (Hachinski). Receiver operating characteristic (ROC) curves were calculated to determine the diagnostic accuracy of Cys C and HDL levels in distinguishing patients with dementia from healthy subjects. Results: We found that plasma Cys C levels were higher, but HDL levels were lower in AD and VaD patients respectively, compared to healthy control subjects. Yet, Cys C levels were highest among patients with VaD. Interestingly, plasma Cys C levels were significantly correlated with IADL Scale scores. In addition, the ROC curves for Cys C (area under the curve, AUC 0.816 for AD, AUC 0.841 for VaD) and HDL (AUC 0.800 for AD, AUC 0.731 for VaD) exhibited potential diagnostic value in distinguishing AD/VaD patients from healthy subjects. While the ROC curve for the combination of Cys C and HDL (AUC 0.873 for AD, AUC 0.897 for VaD) showed higher diagnostic accuracy in distinguishing AD/VaD patients from healthy subjects than the separate curves for each parameter. Conclusions: Our findings suggest that the inflammatory mediators Cys C and HDL may play important roles in the pathogenesis of dementia, and plasma Cys C and HDL levels may be useful screening tools for differentiating AD/VaD patients from healthy subjects.
KW - Alzheimer's disease
KW - Cystatin C
KW - Dementia
KW - High-density lipoprotein
KW - Vascular dementia
UR - http://www.scopus.com/inward/record.url?scp=85014514622&partnerID=8YFLogxK
U2 - 10.3389/fnagi.2017.00026
DO - 10.3389/fnagi.2017.00026
M3 - Article
AN - SCOPUS:85014514622
SN - 1663-4365
VL - 9
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
IS - FEB
M1 - 26
ER -